Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

1142P - Personalized decision making in cutaneous squamous cell carcinoma: Integrating a clinico-pathological model for absolute metastatic risk into the staging systems

Date

21 Oct 2023

Session

Poster session 13

Topics

Staging Procedures;  Cancer in Older Adults

Tumour Site

Basal Cell and Squamous Cell Cancers of the Skin

Presenters

Marlies Wakkee

Citation

Annals of Oncology (2023) 34 (suppl_2): S651-S700. 10.1016/S0923-7534(23)01941-5

Authors

M. Wakkee1, L. Pozza2, H. van de Werken3, A. Mooyaart4, J. Dwarkasing5, S. Alex5, D. Bellomo2, L. Zandwijk-hollestein6, B. Rentroia Pacheco1

Author affiliations

  • 1 Dermatology, Erasmus MC Cancer Institute, 3000CA - Rotterdam/NL
  • 2 Bioinformatics, SkylineDx BV, 3062 ME - Rotterdam/NL
  • 3 Computational Biology And Bioinformatics, Erasmus MC - Erasmus University Rotterdam, 3000 CA - Rotterdam/NL
  • 4 Pathology, Erasmus MC, 3000 CA - Rotterdam/NL
  • 5 Science, SkylineDx BV, 3062 ME - Rotterdam/NL
  • 6 Dermatology, Erasmus MC Cancer Institute, 3000 CA - Rotterdam/NL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1142P

Background

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, causing a staggering death toll comparable to that of melanoma, despite its low propensity to metastasize (2-5%). However, until recently, cSCC has been perceived as a non-life-threatening tumor, and current clinical practices are suboptimal: clinical staging systems cannot consistently and reliably identify patients at high risk of metastasis, and they do not provide absolute metastatic risk. Therefore, decisions about follow-up schedules and treatment cannot be personalized.

Methods

We sought to improve the risk stratification as defined by the American Joint Committee on Cancer (AJCC) and the Brigham and Women's Hospital (BWH), by integrating a recently developed clinico-pathological (CP) model for metastatic risk in cSCC patients. We tried to identify patients at increased risk within the low-risk group (AJCC: T1-T2, BWH: T1-T2a) and in the high-risk group (AJCC: T3-T4, BWH: T2b-T3), We performed our analysis in a Dutch nested case-control cohort (n=390); binarized the 5-year metastatic risk into CP High-Risk and CP Low-Risk, by selecting thresholds based on likelihood ratios.

Results

In the low-risk group, the metastatic risk is 1.1% (AJCC) and 1.2% (BWH). Within this group CP High-Risk patients (AJCC: 2.6%, BWH=1.9%) have an increased risk (AJCC: 10.3%, BWH: 16.2%) and would be offered follow-up; but not the CP Low-Risk patients (AJCC: 97.4%, BWH=98.1%) with a decreased risk (AJCC: 0.9%, BWH: 0.98%). In the high-risk group, the metastatic risk is 5.7% (AJCC) and 12.8% (BWH). Within this group, CP High-Risk (AJCC:7.9 %, BWH=21.8%) have an increased risk (AJCC: 40.5%, BWH: 43.4%) and could be offered more intensive follow-up and treatment (e.g., adjuvant treatment).

Conclusions

Our data show that our risk model can enhance the AJCC and BWH staging systems, by refining the risk stratification in both the low-risk and high-risk groups. This has the potential to help clinicians, dermatologists, radiotherapists, and clinical oncologists make more personalized decisions about more intense follow-up schedules and treatment of their cSCC patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Erasmus MC.

Funding

This study is funded by a PPP Allowance made available by Health∼Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships. In this case a public-private partnership between Erasmus MC and SkylineDx BV.

Disclosure

M. Wakkee: Financial Interests, Institutional, Funding: Sanofi, Regeneron; Financial Interests, Personal, Speaker, Consultant, Advisor: Regeneron. L. Pozza, S. Alex: Financial Interests, Personal, Full or part-time Employment: SkylineDx BV. J. Dwarkasing: Financial Interests, Personal, Full or part-time Employment: SkylineDx BV; Financial Interests, Personal, Stocks/Shares: SkylineDx BV. D. Bellomo: Financial Interests, Personal, Full or part-time Employment: SkylineDx BV; Financial Interests, Personal, Stocks/Shares: SkylineDx. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.